When Cost Blocks Care: Why Medication Affordability Is the Next Frontier in Patient Care
Every day, patients are making agonizing choices to skip medications due to cost, and the fallout is evident in worsening health and avoidable hospitalizations. Health systems are in a prime position to break this cycle by acting as advocates for their patients’ financial as well as physical well-being.
Broadening Biomarker Validation for Alzheimer’s Disease Diagnosis Globally
Demonstrating the clinical utility and cost-effectiveness of innovative blood-based biomarker tests can help pave the way for making timely AD diagnosis and proactive care the norm.
Digital Health Funding in H1 2025: Market Stabilizes, AI Dominates and Exits Return
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw two long-awaited IPOs as well as rising M&A activity, which are two signals of market maturity — but looming policy shifts may challenge long-term growth.
KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease
KalVista Pharmaceuticals’ Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring.
Hospitals Are Investing in AI — How Can They Evaluate ROI?
AI doesn’t need to be a black box — and hospitals don’t need to invest based on blind faith. With the right structure, questions, and metrics in place, healthcare leaders can cut through the hype and make decisions that actually drive value.